India launches first indigenous vaccine for cervical cancer

What is Cervical Cancer ?

Cervical cancer is a type of cancer that first appears in the cervix. All women are susceptible to developing cervical cancer, according to the Centers for Disease Control and Prevention. Women over 30 are most likely to experience it. Cervical cancer is primarily brought on by persistent human papillomavirus (HPV) infection. Early detection of cervical cancer greatly improves treatment options, length of survival, and quality of life.

The vaccine

The first locally developed quadrivalent Human Papilloma Virus (qHPV) vaccine for the prevention of cervical cancer was released today, marking a significant milestone in Indian medical science. The Department of Biotechnology and the Serum Institute of India (SII) are responsible for developing the cervical cancer vaccine (DBT).According to Dr. N. K. Arora, the COVID working group’s chair, the National Technical Advisory Group on Immunization (NTAGI) described the launch of an Indian-made vaccine as an exciting experience.

The updates about the vaccine .

Because this particular virus is the cause of cervical cancer in 85% to 90% of cases and this vaccine protects against those viruses, it is very effective and prevents the disease.”In actuality, this was one of the last significant vaccines to be released. In actuality, this is one of the final vaccines to be introduced into the programme. Now that Indian vaccines will be accessible, we anticipate their introduction into the National Immunization Program for girls aged 9 to 14 years.Adar Poonawalla, CEO of the Serum Institute of India (SII), who was also present, told reporters outside the event that the cervical cancer vaccine would be accessible and cost between $200 and $400. However the final price is not decided yet.

By Subhechcha Ganguly

Rate this post

Subscribe to our Newsletter

Leave a Comment